Authors
Loading...
Analysis reveals lower response rates and poorer survival in AML with multiple FLT3-ITD clones, indicating clonal heterogeneity as a biomarker.
Park et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: